Determination of Blood Tumor Cells

Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .

Completed

Looking for future studies?

Key information

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell Abnormalities Cell Epithelial Chronic Disease Colorectal Cancer, Hereditary Nonpolyposis, Type 8 Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Zurich

Zurich, 8091, Switzerland

About this study

Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood.

Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)

Exclusion criteria

Inability to understand the language of the center (German)

Treatment and study plan

Primary outcomes

Number of CTC / lymphocytes removed

Time frame: 1 day

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Official study title

Determination of Blood Tumor Cells Using Magnetic Nanoparticles

Important dates

Study start: 2017
Primary completion: 2022
Study completion: 2022
First posted: Mar 2, 2020
Registry last updated: Jan 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed